Key Points
- EVP Michael Feld sold 74 BDX shares on December 26 at an average price of $196.08 for $14,509.92, leaving him with 16,506 shares (a 0.45% drop in his ownership); he also reported smaller sales on Dec. 1 and Oct. 27.
- Dividend increase: Becton, Dickinson raised its quarterly dividend to $1.05 (from $1.04), equal to a $4.20 annualized payout and about a 2.2% yield, with record/ex-dividend/payable dates in December.
- Stock and analyst snapshot: BDX trades near $195 with a $55.6B market cap and a P/E of 33.45, a 52-week range of $162.29–$251.99, and a consensus rating of “Hold” with an average price target of $205.64.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 74 shares of the business's stock in a transaction on Friday, December 26th. The shares were sold at an average price of $196.08, for a total transaction of $14,509.92. Following the completion of the sale, the executive vice president directly owned 16,506 shares in the company, valued at $3,236,496.48. This represents a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Michael Feld also recently made the following trade(s):
- On Monday, December 1st, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $193.36, for a total value of $14,502.00.
- On Monday, October 27th, Michael Feld sold 57 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $186.01, for a total value of $10,602.57.
Becton, Dickinson and Company Stock Down 0.7%
BDX stock opened at $195.02 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. The stock has a market capitalization of $55.56 billion, a P/E ratio of 33.45, a P/E/G ratio of 1.81 and a beta of 0.25. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The business has a 50-day moving average of $190.44 and a 200-day moving average of $186.52.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.32 billion for the quarter. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be given a $1.05 dividend. This is a boost from Becton, Dickinson and Company's previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company's payout ratio is presently 72.04%.
Analyst Upgrades and Downgrades
BDX has been the topic of several recent research reports. Royal Bank Of Canada lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a "sector perform" rating in a research note on Wednesday, December 17th. Morgan Stanley lifted their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an "overweight" rating in a research report on Tuesday, December 2nd. Wall Street Zen cut Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Saturday, November 8th. Piper Sandler decreased their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a "neutral" rating for the company in a research note on Friday, November 7th. Finally, Argus upped their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Four analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $205.64.
Check Out Our Latest Stock Report on Becton, Dickinson and Company
Institutional Trading of Becton, Dickinson and Company
Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Becton, Dickinson and Company by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier's stock worth $6,074,750,000 after acquiring an additional 147,041 shares during the last quarter. State Street Corp boosted its position in Becton, Dickinson and Company by 3.4% during the third quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier's stock worth $2,596,496,000 after purchasing an additional 459,219 shares during the period. First Eagle Investment Management LLC increased its holdings in shares of Becton, Dickinson and Company by 13.8% in the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier's stock valued at $1,870,653,000 after purchasing an additional 1,208,218 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Becton, Dickinson and Company by 7.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier's stock valued at $1,712,715,000 after purchasing an additional 636,138 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Becton, Dickinson and Company by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 6,723,702 shares of the medical instruments supplier's stock worth $1,153,157,000 after buying an additional 244,199 shares during the last quarter. Institutional investors own 86.97% of the company's stock.
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
